CVS Health raised its full-year adjusted earnings forecast on Wednesday after strong demand for COVID-19 vaccinations and tests helped the U.S. healthcare conglomerate beat third-quarter profit estimates.

To combat the public health crisis caused by infections caused by the Delta variant, major U.S. employers have mandated COVID-19 tests and vaccines, while booster shots have been authorized for some age groups and high-risk populations.

Walgreens Boots Alliance also reported a boost from increased demand for vaccinations as a result of the variant's spread.

In the third quarter, CVS said it administered more than 8 million COVID-19 tests and more than 11 million COVID-19 vaccines.

CVS Health Completes Acquisition of Aetna, Marking Start of Transforming  Consumer Health Experience

The company reduced its 2021 expectations for the number of COVID-19 vaccine doses administered at its clinics to a range of 32 million to 36 million in August, down from a prior range of 29 million to 44 million doses, reflecting a slowdown in vaccinations during the second quarter.

CVS is best known for its large chain of drugstores across the United States, but it also has a health insurance business and a pharmacy benefits management unit that helps negotiate lower drug prices for its customers, including employers and health insurers.

Sales in its health insurance unit increased 9.5 % to $20.48 billion, while the medical benefit ratio (MBR), or the percentage of premiums paid for medical services, increased to 85.8 % from 84 % the previous year, owing to higher COVID-19-related costs.

Medical costs for health insurers have been fluctuating since the outbreak of the pandemic. Lower medical claims for non-urgent procedures helped keep costs in check, but COVID-19 vaccinations and care drove them up.

The company's revenue from its pharmacy benefit management unit increased 9.3 % to $39.05 billion.

According to IBES data, excluding items, the company earned $1.97 per share, exceeding estimates of $1.78.

CVS now expects adjusted earnings per share of $7.90 to $8.00 for the full year, up from $7.70 to $7.80 previously.